|Articles|December 14, 2022
Understanding the true cost of transparency reporting
Author(s)PwC
When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, new systems were quickly — and possibly haphazardly — put in place to handle snowballing transparency reporting requirements. Now the cracks are beginning to show, and PLS companies are realizing the true cost of transparency reporting.
Related Content
Trending on PharmExec
1
DTP is Scaling Fast, the Safety Infrastructure is Not
2
U.S. Supreme Court Weighs Inducement Liability Beyond FDA Carve-Out Labels
3
AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial
4
FDA Pauses Release of New CRL’s Following Citizen’s Petition
5